Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | TGM2 | P21980 | 1/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | PLAU | P00749 | 1/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31550495 | 0.90 | ALDH1A1 (0.62) | LMNASMN1; SMN2HTTALDH1A1CA12 | |
| SCHEMBL6741072 | 0.87 | LMNA (0.65) | LMNASMN1; SMN2HTTALDH1A1CA12 | |
| SCHEMBL11783251 | 0.87 | HTT (0.66) | LMNASMN1; SMN2HTTALDH1A1CA12 | |
| SCHEMBL126974 | 0.87 | HTT (0.66) | LMNASMN1; SMN2HTTALDH1A1CA12 | |
| SCHEMBL13055383 | 0.86 | LMNA (0.80) | LMNASMN1; SMN2HTTALDH1A1CA12 | |
| Hydrochloric Acid SCHEMBL8688569 | 0.85 | HTT (0.64) | LMNASMN1; SMN2HTTALDH1A1CA12 | |
| SCHEMBL375858 | 0.85 | LMNA (0.73) | LMNASMN1; SMN2HTTALDH1A1CA12 | |
| SCHEMBL11143560 | 0.85 | LMNA (0.63) | LMNASMN1; SMN2HTTALDH1A1CA12 | |
| SCHEMBL10081124 | 0.85 | LMNA (0.63) | LMNASMN1; SMN2HTTALDH1A1CA12 | |
| SCHEMBL8197237 | 0.85 | LMNA (0.67) | LMNASMN1; SMN2HTTALDH1A1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109665-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20250042843-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2025-02-06 | — | — | US | disclosed |
| US-20230122651-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-20220105194-A1 | CONJUGATE COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | ASTELLAS PHARMA INC. (JP) | 2022-04-07 | — | — | US | disclosed |
| US-20210340276-A1 | COMPLEX HAVING ANTI-HUMAN MUC1 ANTIBODY FAB FRAGMENT, PEPTIDE LINKER AND/OR LIGAND | ASTELLAS PHARMA INC. (JP) | 2021-11-04 | — | — | US | disclosed |
| US-20210122709-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2021-04-29 | — | — | US | disclosed |
| US-20200055813-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2020-02-20 | — | — | US | disclosed |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2019-03-14 | — | — | US | disclosed |
| US-20190040001-A1 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | PARATEK PHARMACEUTICALS, INC. | 2019-02-07 | — | — | US | disclosed |
| US-20190040001-A1 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | PARATEK PHARMACEUTICALS, INC. | 2019-02-07 | — | — | US | disclosed |
| US-20030166585-A1 | Substituted tetracycline compounds as synergistic antifungal agents | PARATEK PHARMACEUTICALS, INC. | 2003-09-04 | — | — | US | disclosed |
| US-20030100017-A1 | Substituted tetracycline compounds as antifungal agents | PARATEK PHARMACEUTICALS, INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2003005971-A2 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | PARATEK PHARMACEUTICALS, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
| WO-2002085303-A2 | SUBSTITUTED TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF MALARIA | PARATEK PHARMACEUTICALS, INC. (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002072031-A2 | SUBSTITUTED TETRACYCLINE COMPOUNDS AS SYNERGISTIC ANTIFUNGAL AGENTS | PARATEK PHARMACEUTICALS, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002072022-A2 | SUBSTITUTED TETRACYCLINE COMPOUNDS AS ANTIFUNGAL AGENTS | PARATEK PHARMACEUTICALS, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
| US-20010038854-A1 | Sustained-release preparation | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2001-11-08 | — | — | US | disclosed |
| US-6264970-B1 | BIODEGRADABLE POLYMER | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| EP-0815853-A2 | Sustained-release preparation for bioactive substance having an acidic group | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-01-07 | — | — | EP | disclosed |
| US-4038306-A | N-T-BUTOXYCARBONYL-S-LOWER ALKANOYLAMIDOMETHYL-CYSTEINE AND P-NITROPHENYL ESTERS | MERCK & CO., INC. (US) | 1977-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220105194-A1 | CONJUGATE COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | MUC1, CA14, CA13 | LMNA 2337/4885SMN1; SMN2 4476/4885HTT 3269/4885 |
| US-20030166585-A1 | Substituted tetracycline compounds as synergistic antifungal agents | TUBB6, ETF1, TUBB2A | LMNA 3309/4885SMN1; SMN2 1859/4885HTT 3268/4885 |
| US-20210340276-A1 | COMPLEX HAVING ANTI-HUMAN MUC1 ANTIBODY FAB FRAGMENT, PEPTIDE LINKER AND/OR LIGAND | MUC1, SIGLEC7, CA14 | LMNA 2413/4885SMN1; SMN2 4502/4885HTT 2215/4885 |
| US-20200055813-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | LMNA 2405/4885SMN1; SMN2 2831/4885HTT 1112/4885 |
| US-20190040001-A1 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | NSUN3, NSUN2, RNMT | LMNA 2369/4885SMN1; SMN2 1627/4885HTT 620/4885 |
| US-20250042843-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | LMNA 2405/4885SMN1; SMN2 2831/4885HTT 1112/4885 |
| US-20260109665-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | CBR1, CYP7A1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | LMNA 2150/4885SMN1; SMN2 2065/4885HTT 1189/4885 |
| US-20010038854-A1 | Sustained-release preparation | BMP2, PGF, AREG | LMNA 1563/4885SMN1; SMN2 1666/4885HTT 4358/4885 |
| US-20230122651-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | LMNA 2405/4885SMN1; SMN2 2831/4885HTT 1112/4885 |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | LMNA 3089/4885SMN1; SMN2 3203/4885HTT 707/4885 |
| US-20210122709-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | LMNA 2405/4885SMN1; SMN2 2831/4885HTT 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.